Biotechnology cancer Cancer screening

A New Tool to Help Fight an Old Enemy – Lung Cancer

November is Lung Cancer Awareness Month and in the United States, lung cancer remains the leading cause of cancer death among both men and women. The primary reason for high death rates for lung cancer is the fact that this disease is typically detected in very late stages, when treatment is often of little use. In 2011, the National Lung Cancer Screening Trial demonstrated that high-risk smokers who received a
Biotechnology cancer Immunotherapies

Tumor Mutational Burden and Response to Immune Checkpoint Therapy

Predicting how patients will respond to anti-cancer therapies can be vital in informing clinical decisions and improving treatment outcome.  Researchers at Rutgers Cancer Institute of New Jersey examined an association between mutational burden and response to immune checkpoint therapy in several cancer types and found that a mutational burden threshold exists in eight cancers that predict response to an immune checkpoint blockade. The work’s co-corresponding authors Shridar Ganesan, MD, PhD,
Biotechnology Clinical Trials Gene Therapy Immunotherapies

Exploring Immunotherapy for Carcinoid and Pancreatic Neuroendocrine Tumors

A clinical trial testing the immunotherapy drug pembrolizumab shows the drug to be well tolerated among patients who have carcinoid or pancreatic neuroendocrine tumors.  Janice M. Mehnert, MD, director of the Phase 1 and Developmental Therapeutics Program at Rutgers Cancer Institute of New Jersey, is the lead author of research that is part of an oral presentation at the European Society for Medical Oncology 2017 Congress taking place this week in
Biotechnology Uncategorized

Three-Week Radiation Therapy Treatment Given Post Mastectomy Is Safe and Effective

Rutgers Cancer Institute of New Jersey research shows low toxicity in shorter treatment course A shorter course of radiation therapy given to breast cancer patients following mastectomy is safe and effective and cuts treatment time in half. That is according to data from a phase II clinical trial conducted by Rutgers Cancer Institute of New Jersey investigators and other colleagues who examined a hypofractionated regimen given over three weeks versus
cancer Cancer Discovery Prodrug

First in Human’ Trial Defines Safe Dosage for Small Molecule Drug ONC201 for Solid Cancer Tumors

Research from Rutgers Cancer Institute of New Jersey examines oral drug that targets cancer cells and spares healthy tissue A ‘first in human’ clinical trial examining the small molecule drug ONC201 in cancer patients with advanced solid tumors shows that this investigational drug is well tolerated at the recommended phase II dose. That’s according to Rutgers Cancer Institute of New Jersey investigators and colleagues whose research also showed early signs